Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis

Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis

Abstract Despite COVID-19’s significant morbidity and mortality, considering cost-effectiveness of pharmacologic treatment strategies for hospitalized patients remains critical to support healthcare resource decisions within budgetary constraints. As such, we calculated the cost-effectiveness of usi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stephen E. Congly, Rhea A. Varughese, Crystal E. Brown, Fiona M. Clement, Lynora Saxinger
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/039dc49a0d224b6b8e76c629176974fd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares